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transcription factors to the promoters of
active genes. But, during a prolonged
fast, CRTC2 is deacetylated by the NAD-
dependent enzyme SIRT1, which allows
for ubiquitination of CRTC2 and degrada-
tion in the proteosome. The authors pro-
vide genetic evidence for this model by
demonstrating that in SIRT1-deficient he-
patocytes, CRTC2 cannot be degraded
even after prolonged exposure to gluca-
gon, which mimics part of the fasting
response. The authors suggest that at
later stages of the fast, deacetylation of
FoxO1 by SIRT1 leads to activation of
FoxO1, thereby maintaining glucose ho-
meostasis. This dual regulatory mecha-
nism is schematized in Figure 1.
A few questions remain for future study.
First, p300 and CBP acetylate many
proteins and, predominantly, histones of
genes primed for expression. Thus, it is
not clear how much of the effects seen
by Liu and colleagues when using p300/
CBP inhibitors in mice is due to CRTC2,
and howmuch to the other p300/CBP tar-
gets. Second, the effects of CRTC2 RNAi
suppression on the expression of PEPCK
were relatively mild, and actually larger at
18 hr than at 6 hr. Some of these issues
will surely be addressed by gene ablation
models for CRTC2 in the future. Third,
while Liu and colleagues propose that
SIRT1-mediated deacetylation of FoxO1
leads to its activation, prior work had
suggested that SIRT1 represses FoxO1
transcription factors (Motta et al., 2004).
This discrepancy was not addressed by
Liu and colleagues but will need to be
resolved in the future. What is clear, how-
ever, is that nature has devised multiple
redundant systems to ensure that the
body’s energy balance is maintained
even in periods of fasting, and that the
liver’s central role in this is controlled
by a complex system of transcriptional
regulators.
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Cholesterol levels in mammalian cells are controlled by an intricate mechanism in which the transcription
factor SREBP plays a key role. Work in this issue (Radhakrishnan et al., 2008) employing direct measurement
of endoplasmic reticulum cholesterol levels offers insights into the ‘‘switch’’ that controls this system with
surprising precision.Mammalian cell cholesterol is under con-
stant, mulitfaceted control. A key part of
this control ismediated by feedback regu-
lation of SREBP, responsible for the tran-
scription of genes encoding sterol syn-
thetic enzymes, LDL receptor, and other
lipid-related proteins. The overarching
concept is simple: when cellular choles-
terol is low, SREBP is activated, leading
to more sterol synthesis and uptake.
When cholesterol is high, SREBP be-comes inactive, leading to less sterol syn-
thesis and uptake.
The understanding of SREBP regula-
tion sets the stage for the work by Rad-
hakrishnan et al. (2008 [this issue]), show-
ing that mammalian cells have a virtual
‘‘toggle switch’’ for responding to lower-
ing cholesterol. The detailed quantitative
picture that begins with these studies
will undoubtedly assist in devising new
strategies for the clinical manipulation ofCell Metabolism 8sterols and provides an example of a bio-
logical switching strategy that may be
widely used.
Our detailed knowledge of SREBP reg-
ulation comes from a remarkable and on-
going odyssey of inquiry by the Brown
and Goldstein laboratory leading to an as-
tonishing collection of basic and medical
insights (Goldstein et al., 2006). SREBP
is an ER membrane protein with an at-
tached cytosolic N-terminal bZIP-HLH, December 3, 2008 ª2008 Elsevier Inc. 451
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Previewstranscription factor. SREBP activation oc-
curs by proteolytic release of the soluble
N-terminal transcription factor, allowing
access to its nuclear targets.
SREBP cleavage is regulated by cho-
lesterol. SREBP resides in the ER, but
the cleaving proteases (S1P and S2P)
are in the Golgi. When cholesterol is low,
SREBP molecules continuously enter the
secretory pathway and travel to the Golgi
where they are cleaved and activated, al-
lowing synthesis of sterol synthesis and
uptake genes. High cholesterol blocks
SREBP trafficking, inhibiting activation by
cleavage. Two proteins allow this highly
selective traffic control. SREBP is bound
to an ER-resident 8-spanning membrane
protein called SCAP (SREBP cleavage-
activating protein) (Hua et al., 1996).
SCAP ferries SREBP to the Golgi by bind-
ing to COPII proteins in ER-to-Golgi trans-
port vesicles. SCAPhas a bilayer-localized
motif called the sterol-sensing domain
(SSD) that specifically binds cholesterol
with high affinity (Radhakrishnan et al.,
2004). Cholesterol binding allows SCAP
to bind to Insig, which prohibits SCAP
from engaging the transport vesicle, thus
preventing SCAP-mediated transport and
cleavage of SREBP. This three-protein
system is responsible for the entirety of
sterol-regulated transcription; that’s a lot
of regulatory bang for one’s protein buck.
This knowledge of SREBP control sets
the stage for a quantitative understanding
of sterol regulation, which is the focus of
the studies by Radhakrishnan et al. The
ER membrane has very low levels of ste-
rols compared to the whole cell, making
it an appropriate environment for the
high-affinity cholesterol sensor SCAP to
reside (Steck and Lange, 2002). Further-
more, natural ‘‘gain’’ in the feedback
loop exists since ER cholesterol levels
are estimated to vary over 10-fold upon
2 fold changes of total cell cholesterol
(Lange and Steck, 1997; Lange et al.,
1999). The authors addressed several
key questions to connect cellular choles-
terol concentrations to SREBP regulation.
First, are the predictions about ER and
whole-cell cholesterol borne out by direct
measurement? Second, what is the rela-
tionship between regulated proteolysis
of SREPB and ER cholesterol levels?
That is, what is the ‘‘dose-response’’ be-
havior of the system? And finally, can
the dose-response behavior of the ER
sensing system be modified?452 Cell Metabolism 8, December 3, 2008 ªTo directly measure ER cholesterol,
Radhakrishnan et al. devised a novel
three-step centrifugational method to pu-
rify ER membranes to a high degree. This
step was critical because even slight con-
tamination of the ER membranes with
cholesterol-rich fractions from other or-
ganelles would cast the analysis into
doubt. Mass spectrometry with internal
standards was used to measure choles-
terol in the highly purified ER membranes
and in whole cells. By raising or lowering
cellular cholesterol, this direct assay was
used to discern the relationship between
cellular and ER cholesterol concentration.
As predicted, ER cholesterol showed
a built-in gain, moving over a 10-fold
range in the face of significantly smaller
fractional changes in whole-cell content.
In the same experiments, the degree of
cleavage of SREBP was also measured,
so that the ER ‘‘dose’’ of cholesterol and
the SREBP cleavage ‘‘response’’ were
discernable over a range of sterol levels.
When SREBP cleavage was plotted
against the ER cholesterol concentration,
the response of the SCAP sensing
system was strikingly sigmoidal, showing
a sudden transition from little to nearly
maximal SREBP cleavage when ER cho-
lesterol falls over a surprisingly small
range, from about 6% to 4%. That is, the
dose-response curve is highly coopera-
tive, resulting in a toggle switch for SREBP
activation. The switch occurs at the same
position along theERmole%axiswhether
thecurve is generatedbydepletionof cho-
lesterol-rich cells or feeding cholesterol-
poor ones and was observed with various
ways of adding or removing cholesterol
from the cells. Importantly, a sterol analog
(25-OH cholesterol) that promotes SCAP-
Insig interaction caused the same switch
without changing ER levels of cholesterol
(Radhakrishnan et al., 2007), indicating
the amenability of the switch as a drug
target.
The switching point can be shifted by
physiological conditions. SCAP-mediated
cleavage depends on the presence of In-
sig proteins (Yang et al., 2002).When cells
with elevated Insig1 expression were
tested, the same steep sigmoid was
shifted 2-fold to the left, meaning that
the SREBP switch occurred at signifi-
cantly lower levels of cholesterol. This is
interesting for at least two reasons. Since
Insigs are under elaborate regulation
(Yabe et al., 2003), this may be part of2008 Elsevier Inc.how the ‘‘switch point’’ is determined in
a given cell or physiological circum-
stance. Also, the fact that the cholesterol
transition is movable indicates that it
might be altered by other means, such
as small molecules or dietary protocols,
possibly providing novel approaches to
clinical management of cholesterol. For
example, a drug that shifted the curve to
regions of no SREBP activation might be
able to lower cholesterol independently
of or even synergistically with statin inhibi-
tion of sterol synthesis.
Traditional biochemistry shows that
highly cooperative behavior requires in-
teracting multiple subunits of an enzyme.
The SCAP protein appears to be a tetra-
mer (Radhakrishnan et al., 2004), and
the measured Hill coefficient of near 4
for the cholesterol transition would be
consistent with a highly cooperative tetra-
meric system. Before deciding SCAP is
amembrane-embedded version of hemo-
globin, it is humbling to consider a few
other features. The Insigs also appear
to be multimeric (Radhakrishnan et al.,
2007), and the response to sterols re-
quires the interaction between SCAP and
Insig. Furthermore, the SREBP cleavage
measured as an endpoint in these studies
is the result of numerous cell processes
that occur after the game of cholesterol-
triggered musical chairs between SCAP
and Insig. It will be interesting to evaluate
the dose-response curve for more up-
stream events, such as the structural tran-
sition that cholesterol causes in SCAP.
Ultimately the structures of these key pro-
teins will have to be discerned in all their
cholesterol binding and multimultimer in-
teracting glory. Until that time, this choles-
terol toggle switch will activate a new level
of quantitative thinking about lipid regula-
tion and cholesterol homeostasis. This
type of analysis is a key step in the crea-
tion of a predictive model for use in both
the basic and clinical understanding of
mammalian sterol homeostasis.
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